Prognostic relevance of MYD88 mutations in CLL: the jury is still out

Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

BALIAKAS Panagiotis HADZIDIMITRIOU Anastasia AGATHANGELIDIS Andreas ROSSI Davide SUTTON Lesley-Ann KMÍNKOVÁ Jana SCARFO Lydia POSPÍŠILOVÁ Šárka GAIDANO Gianluca STAMATOPOULOS Kostas GHIA Paolo ROSENQUIST Richard

Year of publication 2015
Type Article in Periodical
Magazine / Source Blood
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.bloodjournal.org/content/bloodjournal/126/8/1043.full.pdf
Doi http://dx.doi.org/10.1182/blood-2015-05-648634
Field Oncology and hematology
Keywords CHRONIC LYMPHOCYTIC-LEUKEMIA; GENES; SF3B1
Attached files
Description Genome surveys have offered a comprehensive view of the genetic landscape of chronic lymphocytic leukemia (CLL), identifying several recurrently mutated genes, including myeloid differentiation primary response 88 (MYD88). The predominant mutation concerns a p.L265P substitution within exon 5,1,2 which leads to constitutive nuclear factor kappaB stimulation, thus conferring a proliferation and survival advantage to the mutant cells.1 MYD88 mutations reach up to 2% to 5% in CLL and are strikingly enriched among patients expressing mutated IGHV genes (M-CLL).
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info